hepatocellular carcinoma
Conditions
Interventions
Experimental group and control group:DC-CIK
Sponsors
Eastern Hepatobiliary Surgery Hospital
Eligibility
Sex/Gender
All
Age
27 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1. Diagnosis of hepatocellular carcinoma by imaging and AFP; 2. Initial diagnosis and treatment, the patient is unable for surgical treatment; Had not received previous sorafenib, microwave, radio frequency, radiation and any other systemic therapy; 3. BCLC C; 4. Normal organ function; 5. Expected survival = 12 weeks; 6. For this study has been fully understood and voluntarily signed informed consent; 7. approved by the hospital ethics committee.
Exclusion criteria
Exclusion criteria: 1. Pregnant or lactating women; 2. Known for contrast agents, chemotherapy drugs, interleukin-drug allergy or allergy to all biological agents; 3. Severe liver function impairment, Child-Pugh grade C and above in phases; 4. Suffering from any other malignancy within five years; 5. There uncontrolled active infection clinically; 6. With severe systemic disease, systemic failure by the situation; 7. Also accept other systemic anti-cancer therapy (radiotherapy of bone metastases is not restricted); 8. Estimates of the lack of compliance of patients to participate in clinical research.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| OS; | — |
Secondary
| Measure | Time frame |
|---|---|
| Lymphocyte subsets;PFS; | — |
Contacts
Public ContactQu Zengqiang
Eastern Hepatobiliary Surgery Hospital
Outcome results
None listed